Advertisement

Advertisement

2018 ASH Annual Meeting

Advertisement

Advertisement



Sep
16
Today In Oncology
Selpercatinib in RET Fusion–Positive NSCLC
KEYNOTE-024 Survival Update
Final Overall Survival Results of IMpower131 Trial in Advanced Squamous NSCLC
Addition of Durvalumab to Chemotherapy Improves OS in Patients With Extensive-Stage SCLC
5-Year Outcomes With Nivolumab vs Docetaxel in Previously Treated NSCLC
View More 
Advertisement
Most Read Stories
USPSTF Recommendation on Medication Use to Reduce Breast Cancer Risk
WCLC 2019: Final Overall Survival Results of IMpower131 Trial in Advanced Squamous NSCLC
Many Choices Now for Men With Metastatic Hormone-Sensitive Prostate Cancer: How to Decide?
WCLC 2019: CASPIAN Trial Finds Addition of Durvalumab to Chemotherapy Improves Overall Survival in Patients With Extensive-Stage SCLC
'Oral Cryotherapy' for Patients Undergoing Oxaliplatin-Based Chemotherapy
View More 
Most Viewed Videos
Cristina Merkhofer, MD, MHS, on NSCLC: Survival Impact of Taking Part in a Clinical Trial
Gary H. Lyman, MD, MPH, on Myeloid Growth Factors: New Biosimilar Approvals
Ryan Huey, MD, on the Financial Toxicity of Early-Phase Clinical Trials
Grace C. Hillyer, EdD, MPH, on Enrolling Patients in Clinical Trials: Improving Clinician-Patient Communication
Nadine Housri, MD, on Online Tumor Boards: A New Resource for Practicing Oncologists
View More 
© 2019 HSP News Service, L.L.C.